GlassScriptPhysician profile
Delliah A Stampp
NPI 1538342860
$20,563.39
in general payments reported to CMS, 2019-2025
44 companies · $1,466 in 2025
The $1,466 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,125 · 2020: $2,364 · 2021: $2,182 · 2022: $8,866 · 2023: $968 · 2024: $1,593 · 2025: $1,466.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,025.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk As | $6,146.70 | 2022 | |
| Novo Nordisk INC | $3,366.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $2,074.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $1,213.18 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,196.17 | 2019-2024 | Ofev |
| Amgen INC. | $1,065.02 | 2019-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $693.26 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $553.00 | 2019-2022 | |
| Pfizer INC. | $492.53 | 2019-2025 | |
| Glaxosmithkline, LLC. | $486.73 | 2019-2024 | Arexvy, Bexsero, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $443.54 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $427.08 | 2019-2022 | |
| Abiomed | $246.35 | 2023-2024 | Impella |
| Shockwave Medical, INC | $200.03 | 2025 | |
| Janssen Pharmaceuticals, INC | $184.97 | 2019-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delliah Stampp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.